Loading company…
TORL BioTherapeutics develops antibody-based treatments for cancer.
TORL BioTherapeutics develops antibody-based cancer treatments, including clinical-stage programs targeting CLDN6 and CLDN 18.2 and preclinical antibody-drug conjugates and monoclonal antibodies. Founded in 2018 in California, US, the company raised USD 96 million in Series C funding in October 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in